A-shares closed · 港股休市 Quotes 行情 · 28 Sep 16:29 CST
28 Sep 2026 · 20:02 CST Terminal Access 终端入口 →
688301.SH上海证券交易所 · 科创板 STAR

IRAY Group 奕瑞科技

Medical Devices 医疗器械
¥84.97−¥4.13 · −4.64%Delayed 行情延迟 · 28 Sep 2026 · 16:14 CST · CNY
Open 开盘
¥88.25
High 最高
¥88.50
Low 最低
¥82.44
Prev Close 昨收
¥89.10
Volume 成交量
834.5万股
Turnover 成交额
¥7.05亿
Mkt Cap 总市值
¥266亿
P/E 市盈率
36.9×
Recent Activity 近期动态All Filings 全部公告 →

13 significant filings since 31 May 2026: 3 on major holder selling, 3 on share issue and 3 on buyback, and 2 other kinds. The latest, on 8 Aug 2026: 奕瑞科技关于股东减持股份结果公告.
自 31 May 2026 起有 13 份重大公告:major holder selling 3 份、share issue 3 份、buyback 3 份,另有 2 类。最新一份(8 Aug 2026):奕瑞科技关于股东减持股份结果公告。

Price History 价格走势

125 trading days 个交易日 · High 最高 ¥146.13 · Low 最低 ¥73.49
8090100110120130140
Volume 成交量
2,324.6万
Mar 26May 26Jul 26Aug 26Sep 26

As of 25 Sep 2026 截至2026年9月25日

Assessment 评估

IRAY Group 奕瑞科技 is a medical devices company listed on the Shanghai Stock Exchange since 18 Sep 2020. It reported revenue of RMB2.25bn in 2025, up 22.9% from RMB1.83bn in 2024. Attributable net profit rose to RMB650.0m from RMB465.2m, a +39.7% increase. Net profit excluding non-recurring items grew by 41.1%. Operating cash flow per share was RMB6.16 in 2025, ahead of net profit, with a cash flow to profit ratio of 2.06x. As of 30 Jun 2026, the company had a healthy balance sheet with liabilities to assets at 38.7%, a current ratio of 3.38 and a quick ratio of 2.87. The first half of 2026 showed strong revenue growth of 56.7% and a net profit rise of +21.2%. The company remains profitable with improving cash flow and solid margins.

奕瑞科技是一家医疗器械公司,2020年9月18日在上交所上市。2025年营业收入22.51亿元,较2024年18.31亿元同比上升22.9%;归母净利润6.50亿元,较4.65亿元上升39.7%;扣非后净利润同比上升41.1%。2025年每股经营现金流6.16元,经营现金流与净利润之比达2.06倍,现金生成能力良好。截至2026年6月30日,资产负债率38.7%,流动比率3.38,速动比率2.87,财务结构稳健。2026年上半年营业收入同比+56.7%,归母净利润同比+21.2%。公司持续盈利,现金流改善,毛利率和净利率保持较高水平。

What to Watch 关注要点
  • Revenue growth in the full year 2026 compared to 2025
    2026全年营业收入较2025年的同比变化
  • Attributable net profit for the full year 2026
    2026全年归属于母公司股东的净利润
  • Operating cash flow per share in 2026
    2026年每股经营现金流
  • Changes in shareholding structure, especially of the largest holder
    第一大股东持股比例变动情况
  • Next distribution policy, including cash dividend and share bonus
    下一次分红方案中的现金分红及送转股安排
  • Number and size of new acquisitions or equity transfers
    新增收购或股权转让事项的数量及对价
Facts 事实
  • Company: IRAY Group 奕瑞科技, Shanghai Stock Exchange 688301; industry Medical Devices; listed 18 Sep 2020.
    公司:奕瑞科技,上海证券交易所 688301;行业:医疗器械;上市日期:2020年9月18日。
  • Close on 24 Sep 2026 RMB89.10; close on 24 Sep 2025 RMB116.81, RMB82.95 in today's terms; one-year change, adjusted for distributions and share changes +7.4%.
    2026年9月24日收盘价89.10元;2025年9月24日收盘价116.81元(前复权82.95元);一年涨跌幅(复权)+7.4%。
  • 52-week range in today's terms, adjusted for distributions and share changes RMB68.88 to RMB146.13.
    52周区间(前复权)68.88元至146.13元。
  • In the last 12 months 2 trading days closed 9% or more above or below the day before (all days, not only this year). The 2 most recent of them: 14 May 2026 +13.3%; 30 Jun 2026 +10.7%. No two of the 2 fell on consecutive trading days.
    近12个月共有2个交易日收盘涨跌幅达9%及以上(为全部交易日,不限于今年)。其中最近2个:2026年5月14日 +13.3%;2026年6月30日 +10.7%。其中任意两个交易日均不相邻。
  • Market capitalisation RMB27.93bn; P/E TTM 38.7; price to book 3.60x.
    总市值279.25亿元;市盈率(TTM)38.7;市净率3.60倍。
  • Revenue 2025 RMB2.25bn; 2024 RMB1.83bn; change +22.9%.
    营业收入2025年22.51亿元;2024年18.31亿元;同比+22.9%。
  • Attributable net profit 2025 RMB650.0m; 2024 RMB465.2m; change +39.7%.
    归属于母公司股东的净利润2025年6.50亿元;2024年4.65亿元;同比+39.7%。
  • Net profit excluding non-recurring items, 2025 change +41.1%.
    2025年扣除非经常性损益后的净利润同比+41.1%。
  • Basic EPS 2025 RMB3.20; 2024 RMB2.33.
    基本每股收益2025年3.20元;2024年2.33元。
  • Operating cash flow per share 2025 RMB6.16; 2024 RMB2.52; operating cash flow to net profit 2.06x.
    每股经营现金流2025年6.16元;2024年2.52元;经营现金流与净利润之比2.06倍。
  • 2025 gross margin 51.4%; net margin 28.1%; ROE 13.1%.
    2025年毛利率51.4%;净利率28.1%;净资产收益率13.1%。
  • At 30 Jun 2026: liabilities to assets 38.7%; current ratio 3.38; quick ratio 2.87; receivable days 94; inventory days 177.
    截至2026年6月30日:资产负债率38.7%;流动比率3.38;速动比率2.87;应收账款周转天数94;存货周转天数177。
  • Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB1.67bn, change +56.7%; attributable net profit RMB405.7m, change +21.2%; operating cash flow per share RMB1.21.
    截至2026年6月30日的报告期(六个月,不可与上述全年数据直接比较):营业收入16.71亿元,同比+56.7%;归母净利润4.06亿元,同比+21.2%;每股经营现金流1.21元。
  • Ownership: actual controller Tieer Gu; largest holder at 30 Jun 2026: 上海奕原禾锐投资咨询有限公司, 13.21%.
    股权:实际控制人:Tieer Gu;2026年6月30日第一大股东:上海奕原禾锐投资咨询有限公司,持股13.21%。
  • Latest distribution: ex-date 12 Jun 2026, cash RMB1.00 per share and 4 new shares for every 10 held.
    最近一次分配:除权除息日2026年6月12日,每股现金1.00元,每10股送转4股。
  • Acquisitions and equity transfers filed in the last 12 months: 2; largest consideration not shown.
    近12个月披露的收购与股权转让:2项;最大对价未披露。
  • Aurelian Grade C, score 63.2 of 100, graded within a peer group of 140 companies in its industry; no rank among peers is given.
    金源评级C,得分63.2(满分100),于行业同业140家中评定;未提供其在同业中的排名。
  • Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
    本报告未掌握:应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。